Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.60    -0.35 (-4.00%)
Bid:
8.20
Ask:
9.00
Spread: 0.80 (9.756%)
Market Cap: £55.03m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

New Contracts

14 Jul 2021 07:00

RNS Number : 1425F
Kromek Group PLC
14 July 2021
 

14 July 2021

 

Kromek Group plc

("Kromek" or the "Group")

 

New Contracts

Kromek wins new contracts and orders across all segments for delivery this year

 

Kromek (AIM: KMK), a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, announces that it has received new contracts and repeat orders across all of its target segments as commercial momentum continues to increase across the business. All of the contracts are for delivery in the Group's current financial year (except as otherwise indicated).

 

In the nuclear detection segment, Kromek has received an order worth £173,000 from its UK government-related customer for the Group's D5 RIID high-performance radiation detector designed for challenging environments. This represents the first major order for the D5 RIID following its launch last year. The Group has also received a €78,000 repeat order from the European Commission for its D3S ID portable radiation detector.

 

An $84,000 repeat order has been received from a US medical imaging customer, which is using Kromek's detectors in its systems for nuclear medicine applications. Following the customer's recent receipt of FDA approval for this system, the Group expects to be awarded a multi-year supply contract in due course.

 

In its new target area of biological-threat detection, Kromek has been awarded a £349,000 contract with the UK Ministry of Defence, through its Defence and Security Accelerator Open Call for Innovation programme, to develop its technology to meet defence and security requirements for wide-area monitoring of biological pathogens. The work will build upon Kromek's existing capabilities in airborne pathogen detection and will run until November 2022.

 

In security screening for industrial applications, the Group has been awarded a $250,000 repeat order from a US-based customer that is a global leader in aerospace and defence technologies servicing the US Department of Defense. The Group's detectors are designed into the customer's system that is used for ammunition scanning and the Group is the exclusive supplier of these detectors under a ten-year agreement signed in 2017. The Group expects to receive further orders from this customer over the coming years.

 

Dr Arnab Basu, CEO of Kromek, said: "It is great to be winning contracts and orders across our target markets as our customers increasingly return to pre-pandemic trading patterns. We're proud to be furthering our partnerships with the UK and US defence forces, including receiving our first major order for the D5 RIID, and we're very excited about the prospects for our biological-threat detection solution, with the latest award being particularly focused on emerging and novel threats. At the same time, our medical imaging order is typical of the growing trend of OEM customers receiving approval for their next-generation scanners containing our detectors, which leads to increased demand for our technology as they prepare for rollout. All of this adds to our visibility for the year ahead as we remain on track to deliver significant growth." 

 

 

For further information, please contact:

 

Kromek Group plc

Arnab Basu, CEO

Paul Farquhar, CFO

+44 (0)1740 626 060

 

Cenkos Securities plc (Nominated Adviser and Broker)

Camilla Hume/Giles Balleny (NOMAD)

Julian Morse (Sales)

+44 (0)20 7397 8900

 

Luther Pendragon (Financial PR)

Harry Chathli

Claire Norbury

+44 (0)20 7618 9100

 

 

About Kromek Group plc

 

Kromek Group plc is a technology group (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT") and other advanced technologies. Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

The Group's business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over 150 full-time employees across its global operations. Further information on Kromek Group is available at www.kromek.com and

https://twitter.com/kromekgroup.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTRJMMTMTABTMB
Date   Source Headline
4th Jun 20267:00 amRNSGrant of Long-Term Incentives
2nd Jun 20267:00 amRNS-RLaunch of new interactive investor hub
1st Jun 20267:00 amRNSPDMR/Director Shareholding, Issue of Equity & TVR
12th May 20267:00 amRNSFull Year 2026 Trading Update
30th Apr 20262:30 pmRNSIssue of Equity, TVR & Extension of Options
9th Mar 20261:36 pmRNSDirector Share Purchase
9th Mar 20261:36 pmRNSDirector Share Purchase
20th Jan 20267:00 amRNSInterim Results
16th Dec 20257:00 amRNSNotice of Results
15th Dec 202512:27 pmRNSHolding(s) in Company
3rd Nov 202511:32 amRNSDirector Share Purchase
28th Oct 20257:00 amRNSGrant of Options, PDMR Dealings and TVR
27th Oct 20252:16 pmRNSResult of AGM
27th Oct 20257:00 amRNSPre-close Trading Statement
3rd Oct 202510:06 amRNSNotice of AGM and Publication of Annual Report
16th Sep 20257:00 amRNSFinal Results
11th Aug 20257:00 amRNSNew Biosecurity Award from UK MoD
28th Jul 20257:00 amRNS$5m received under Siemens Healthineers agreement
21st Jul 20257:00 amRNS£1.7m contract win under UK Government Framework
23rd Jun 202511:40 amRNS-RCapital Markets Day Presentation
18th Jun 20257:00 amRNSCapital Markets Day
16th Jun 20254:02 pmRNSHolding(s) in Company
9th Jun 20257:00 amRNSIssue of Equity and Total Voting Rights
3rd Jun 20251:53 pmRNSHolding(s) in Company
3rd Jun 20257:00 amRNSCapital Markets Day
28th May 20257:00 amRNSNew Nuclear Security Orders
8th May 20257:05 amRNSDirectorate Change
8th May 20257:00 amRNSFull Year 2025 Trading Update
17th Feb 20257:00 amRNS$25m received under Siemens Healthineers agreement
7th Feb 20251:49 pmRNSHolding(s) in Company
6th Feb 202512:35 pmRNSHolding(s) in Company
30th Jan 20257:01 amRNSInterim Results
30th Jan 20257:00 amRNSKromek Signs Agreements with Siemens Healthineers
13th Dec 202412:20 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM and Publication of Annual Report
28th Oct 20247:01 amRNSFinal Results and Publication of Annual Report
28th Oct 20247:00 amRNSFinancing Update
30th Sep 20247:00 amRNSUpdate on Full Year Results
23rd Sep 20247:00 amRNSKromek selected for UK Government Framework
16th Sep 20247:00 amRNSKromek awarded £2.0m contract from UK MOD
21st Aug 202410:14 amRNSHolding(s) in Company
7th Jun 20249:20 amRNSCancellation of outstanding Convertible Loan Notes
29th May 20247:00 amRNSFY 2024 Trading Update
25th Apr 20247:00 amRNSKromek receives new Nuclear Security contract
3rd Apr 20243:13 pmRNSDirector/PDMR Shareholding
26th Mar 20247:00 amRNSKromek receives $2.1m security screening order
6th Mar 20243:21 pmRNSHolding(s) in Company
4th Mar 202412:16 pmRNSHolding(s) in Company
4th Mar 202411:51 amRNSResult of General Meeting
5th Feb 202410:17 amRNSConversion of £1.5m of Convertible Loan Notes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.